Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Sep 08, 2023

SELL
$16.97 - $22.03 $1,629 - $2,114
-96 Reduced 65.75%
50 $1.02 Million
Q1 2023

May 11, 2023

BUY
$15.96 - $23.15 $2,330 - $3,379
146 New
146 $2.66 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.02B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Tucker Asset Management LLC Portfolio

Follow Tucker Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tucker Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tucker Asset Management LLC with notifications on news.